• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤区域阳性(TAP)评分程序性死亡配体 1(PD-L1):一种联合肿瘤细胞和免疫细胞评分的新型可视化评估方法。

Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring.

机构信息

Roche Tissue Diagnostics, 1910 E. Innovation Park Dr., Oro Valley, Tucson, AZ, 85755, USA.

出版信息

Diagn Pathol. 2023 Apr 19;18(1):48. doi: 10.1186/s13000-023-01318-8.

DOI:10.1186/s13000-023-01318-8
PMID:37076889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10114344/
Abstract

BACKGROUND

Determination of programmed death-ligand 1 (PD-L1) protein expression level in tumor cells and tumor-associated immune cells is critical for identifying patients eligible for immunotherapy. PD-L1 manual scoring algorithms can generally be divided into two categories: cell counting and visual estimation. Cell counting can be time-consuming and is not in sync with pathology practice, which classically uses a Gestalt approach based on pattern recognition and visual estimation. In this study, we introduce the Tumor Area Positivity (TAP) score, which is a novel, straightforward method for scoring tumor cells and immune cells together using visual estimation.

METHODS

To demonstrate the reproducibility of TAP scoring among pathologists, between- and within-reader precision studies were performed both within (internal) and outside of (external) our organization. We also compared the TAP score to the Combined Positive Score (CPS), which is based on cell counting, for concordance and time efficacy.

RESULTS

The average positive agreement, average negative agreement, and overall percent agreement between and within readers were all above 85% for both internal and combined external reader precision studies. TAP score had high concordance rate at 5% cutoff compared with CPS at cutoff 1: positive percent agreement, negative percent agreement, and overall percent agreement were all above 85%.

CONCLUSIONS

Our study showed the TAP scoring method to be straightforward, significantly less time-consuming, and highly reproducible with a high concordance rate between TAP score and CPS.

摘要

背景

在肿瘤细胞和肿瘤相关免疫细胞中测定程序性死亡配体 1(PD-L1)蛋白表达水平对于确定适合免疫治疗的患者至关重要。PD-L1 手动评分算法通常可分为两类:细胞计数和视觉估计。细胞计数可能很耗时,并且与病理实践不同,病理实践通常基于基于模式识别和视觉估计的整体方法使用 Gestalt 方法。在这项研究中,我们介绍了肿瘤区域阳性(TAP)评分,这是一种新颖的,简单的方法,可用于通过视觉估计一起对肿瘤细胞和免疫细胞进行评分。

方法

为了证明病理学家之间 TAP 评分的可重复性,我们在内部和外部进行了读者间和读者内的精确性研究。我们还将 TAP 评分与基于细胞计数的组合阳性评分(CPS)进行了比较,以评估一致性和时间效率。

结果

内部和组合外部读者精度研究中,读者间和读者内的平均阳性一致性,平均阴性一致性和总体百分比一致性均高于 85%。与 CPS 在 1:阳性百分比一致性,阴性百分比一致性和总体百分比一致性均高于 85%的 5%截断值相比,TAP 评分具有很高的一致性率。

结论

我们的研究表明,TAP 评分方法简单,耗时明显减少,并且具有很高的重复性,TAP 评分与 CPS 之间具有很高的一致性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/f9f13bf173b2/13000_2023_1318_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/19ca873cc7b0/13000_2023_1318_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/af634304d98a/13000_2023_1318_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/e9f1d2b281f1/13000_2023_1318_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/f9f13bf173b2/13000_2023_1318_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/19ca873cc7b0/13000_2023_1318_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/af634304d98a/13000_2023_1318_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/e9f1d2b281f1/13000_2023_1318_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/10114344/f9f13bf173b2/13000_2023_1318_Fig4_HTML.jpg

相似文献

1
Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring.肿瘤区域阳性(TAP)评分程序性死亡配体 1(PD-L1):一种联合肿瘤细胞和免疫细胞评分的新型可视化评估方法。
Diagn Pathol. 2023 Apr 19;18(1):48. doi: 10.1186/s13000-023-01318-8.
2
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.一项多机构研究,旨在评估免疫组织化学自动全片评分在非小细胞肺癌中评估程序性死亡配体1(PD-L1)表达的应用。
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.
3
A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.四组程序性死亡配体 1 免疫组化检测试剂盒在三阴性乳腺癌评分中的读者间和检测间一致性的多中心分析比较研究。
Histopathology. 2021 Mar;78(4):567-577. doi: 10.1111/his.14254. Epub 2020 Nov 27.
4
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.一项非小细胞肺癌中 PD-L1 表达的前瞻性、多机构、基于病理学家的 4 种免疫组化检测评估。
JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.
5
Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.四种程序性死亡配体 1(PD-L1)免疫组织化学检测方法在三阴性乳腺癌中的检测结果的批内和批间及观察者间可比性研究。
Breast. 2021 Dec;60:238-244. doi: 10.1016/j.breast.2021.11.003. Epub 2021 Nov 6.
6
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.程序性死亡受体1配体(PD-L1)诊断测试:评分算法和测试验证指标的系统文献综述
Diagn Pathol. 2018 Feb 9;13(1):12. doi: 10.1186/s13000-018-0689-9.
7
Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.妇科病理学家之间程序性死亡配体 1(PD-L1)联合阳性评分(CPS)解读的观察者间一致性。
Am J Surg Pathol. 2023 Aug 1;47(8):889-896. doi: 10.1097/PAS.0000000000002058. Epub 2023 Jun 5.
8
Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring.联合阳性评分法检测转移性三阴性乳腺癌中 22C3 和 E1L3N 抗体的 PD-L1 表达的一致性。
Appl Immunohistochem Mol Morphol. 2024 Oct 1;32(9):417-424. doi: 10.1097/PAI.0000000000001223. Epub 2024 Sep 20.
9
Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.程序性死亡配体 1(PD-L1)/甲状腺转录因子-1 双重免疫组织化学染色有助于对肺腺癌患者细胞学标本中肿瘤 PD-L1 表达进行评分。
Cancer Cytopathol. 2021 Feb;129(2):148-155. doi: 10.1002/cncy.22359. Epub 2020 Sep 25.
10
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.多机构研究病理学家对胃癌或胃食管结合部癌程序性细胞死亡配体-1 联合阳性评分免疫组织化学检测的解读。
Mod Pathol. 2023 May;36(5):100128. doi: 10.1016/j.modpat.2023.100128. Epub 2023 Feb 13.

引用本文的文献

1
Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives.妇科肿瘤学中的免疫检查点抑制剂:现状与展望
Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1:166-188. doi: 10.1002/ijgo.70280.
2
PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis.胆管癌中PD-L1的表达:不同抗体克隆的比较及其作为化疗免疫治疗反应预测指标的作用:一项荟萃分析
JCO Precis Oncol. 2025 May;9:e2400475. doi: 10.1200/PO-24-00475. Epub 2025 May 29.
3
Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives.

本文引用的文献

1
Granulocytes and Cells of Granulocyte Origin-The Relevant Players in Colorectal Cancer.粒细胞和粒细胞来源细胞——结直肠癌的相关参与者。
Int J Mol Sci. 2021 Apr 6;22(7):3801. doi: 10.3390/ijms22073801.
2
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors.血小板 PD-L1 抑制 PD-L1 阴性肿瘤中的抗肿瘤免疫细胞活性。
Sci Rep. 2020 Nov 9;10(1):19296. doi: 10.1038/s41598-020-76351-4.
3
Unique pattern of neutrophil migration and function during tumor progression.在肿瘤进展过程中,中性粒细胞迁移和功能呈现独特模式。
胃癌免疫治疗时代的预测性生物标志物:当前成果与未来展望
Front Immunol. 2025 May 14;16:1599908. doi: 10.3389/fimmu.2025.1599908. eCollection 2025.
4
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.阿替利珠单抗治疗高危局部晚期头颈部鳞状细胞癌:一项随机临床试验
JAMA. 2025 May 13;333(18):1599-1607. doi: 10.1001/jama.2025.1483.
5
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.一线替雷利珠单抗联合化疗治疗程序性死亡配体1表达≥1%的晚期胃癌:RATIONALE-305回顾性分析
Adv Ther. 2025 May;42(5):2248-2268. doi: 10.1007/s12325-025-03133-7. Epub 2025 Mar 13.
6
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.一线替雷利珠单抗联合化疗治疗程序性死亡配体1表达≥1%的食管鳞状细胞癌:RATIONALE-306回顾性分析
Adv Ther. 2025 May;42(5):2269-2284. doi: 10.1007/s12325-025-03115-9. Epub 2025 Mar 13.
7
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).2025年食管癌生物标志物:西班牙医学肿瘤学会(SEOM)和西班牙病理学会(SEAP)的最新共识声明
Clin Transl Oncol. 2025 Mar 12. doi: 10.1007/s12094-025-03865-6.
8
Correction: Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring.更正:程序性死亡配体1(PD-L1)的肿瘤区域阳性(TAP)评分:一种用于联合肿瘤细胞和免疫细胞评分的新型视觉评估方法。
Diagn Pathol. 2025 Feb 18;20(1):20. doi: 10.1186/s13000-025-01605-6.
9
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns.胃食管肿瘤分子生物标志物的现状及共表达模式的潜在策略
Cancers (Basel). 2025 Jan 21;17(3):340. doi: 10.3390/cancers17030340.
10
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.免疫细胞因子西姆鲁卡福斯 Alfa(FAP-IL2v)联合帕博利珠单抗治疗晚期和/或转移性黑色素瘤的 Ib 期研究。
Cancer Res Commun. 2025 Feb 1;5(2):358-368. doi: 10.1158/2767-9764.CRC-24-0601.
Nat Immunol. 2018 Nov;19(11):1236-1247. doi: 10.1038/s41590-018-0229-5. Epub 2018 Oct 15.
4
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究:Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
5
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.程序性死亡受体1配体(PD-L1)诊断测试:评分算法和测试验证指标的系统文献综述
Diagn Pathol. 2018 Feb 9;13(1):12. doi: 10.1186/s13000-018-0689-9.
6
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
7
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
8
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.程序性死亡受体配体1(PD-L1)表达作为癌症免疫治疗中的预测生物标志物
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.